logo-loader
viewZacks Small-Cap Research

Zacks Investment Research analyst covers current trends in biotech industry

Zacks Investment Research Inc Biotechnology Analyst John Vandermosten speaks to Proactive Investors at the MicroCap Conference in New York. 

Vandermosten commented on Antares Pharma (NASDAQ:ATRS), and how the biotech's testosterone drug has just gained FDA approval.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

K2fly's Brian Miller reports near doubling in quarterly revenues

K2fly Ltd's (ASX:K2F) Brian Miller tells Proactive's Andrew Scott they've raised record invoices valued at approximately $1.63 million in the March quarter - that's an improvement of 94% over the corresponding quarter of 2019. He says it brings the total invoicing for this financial year to...

6 hours, 6 minutes ago

2 min read